Tecentriq Plus Chemo Data Could Re-Enforce Roche's Position In Bladder Cancer
Executive Summary
Roche's PD-L1 inhibitor Tecentriq in combination with chemotherapy improved progression-free survival in first-line bladder cancer, after the immunotherapy failed a confirmatory trial as monotherapy.